Guotai Junan Securities: Focus on AI + healthcare, high-quality innovation, and value targets with stable performance
I'm LongbridgeAI, I can summarize articles.Guotai Junan Securities released a research report, focusing on companies in AI + healthcare, high-quality innovation, and stable performance. It emphasizes that R&D innovation in the pharmaceutical industry is the core driving force, and AI technology will change drug development and medical services. It suggests paying attention to companies with differentiated innovation capabilities and overseas potential, such as Novogene and Mindray. It is expected that the performance of the pharmaceutical sector will show differentiation in 2024, with the pharmaceutical segment experiencing rapid growth, while the medical device segment may be affected by anti-corruption measures and delayed bidding
According to the Zhitong Finance APP, Guosen Securities released a research report stating that high-quality R&D innovation is the core driving force of the pharmaceutical industry. The commercialization of innovative drugs and devices in China has been well validated, and the revenue from external business development (BD) as well as potential overseas commercialization revenue will be a continuous growth driver for the sector. The firm continues to be optimistic about companies with differentiated innovation capabilities and overseas potential. The centralized procurement process for consumables is still ongoing, and some sub-sectors, such as orthopedics, have entered the post-centralized procurement cycle, suggesting a focus on undervalued leading companies. The pharmaceutical industry is undergoing a transformation period of digitalization and intelligent upgrading, with AI set to change various fields including drug development, medical imaging, multi-omics diagnosis, and medical services.
Guosen Securities' main viewpoints are as follows:
Rapid development of AI technology, focus on AI applications in the healthcare sector.
The healthcare industry is undergoing a transformation period of digitalization and intelligent upgrading. ARK Invest's recent report "Big Ideas 2025" mentioned that using artificial intelligence to "operate" data will disrupt diagnosis, drug discovery, and treatment. Healthcare is the most important application field for AI technology, with broad prospects and imaginative space. The Chinese healthcare industry is welcoming its own "DeepSeek moment." Suggested areas of focus include: 1) AI + multi-omics: Novogene, KingMed Diagnostics; 2) AI + precision diagnosis: Jiuzhou Bio, Shengxiang Bio, Aide Bio; 3) AI + medical devices: Mindray, United Imaging, Kaili Medical, Xiangsheng Medical; 4) AI + chronic disease management: Yuyue Medical, SanNu Bio, Jiuan Medical; 5) AI + pharmaceuticals: WuXi AppTec, Chengdu XianDao, Yaoshi Technology, Haoyuan Pharmaceutical, Jingtai Holdings; 6) AI + medical services: Gushengtang, Aier Eye Hospital, Puri Eye Hospital.
Performance differentiation in the sector in 2024, focus on high-quality innovation and favorable bidding and procurement cycles.
Industry policies, fiscal pressures, centralized procurement, and bidding cycles have had a certain impact on the performance of pharmaceutical companies in 2024, leading to differentiated performance among different sectors. The pharmaceutical sector has achieved relatively rapid growth driven by innovative drugs. The traditional Chinese medicine sector has seen steady growth, but attention is still needed on the pace of centralized procurement. In the medical device sector, companies primarily focused on equipment are expected to be affected by anti-corruption measures and delayed bidding, putting pressure on growth; consumable companies are expected to see high growth rates, especially orthopedic companies that are expected to welcome a sector-wide performance turning point; companies in the upstream of low-consumption and medical devices that were affected by overseas destocking last year are expected to achieve further recovery both year-on-year and quarter-on-quarter. CXO companies with a large proportion of overseas business are expected to show a quarterly recovery trend in both existing and newly signed orders; while upstream life sciences companies are still under profit pressure, the year-on-year decline is narrowing, and demand is improving quarter by quarter. Medical service companies are experiencing weak consumer demand, showing single-digit internal growth.
February 2025 investment portfolio: A-shares: Mindray, WuXi AppTec, New Industry, Kaili Medical, Meihao Medical, Aohua Endoscopy, Aide Bio, Zhend Medical, Yaokang Bio, KingMed Diagnostics; H-shares: Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo Ya-B, Sanofi Biopharmaceuticals, Aikang Medical Risk Warning: Risk of research and development failure; risk of commercialization falling short of expectations; geopolitical risk; risk of policy exceeding expectations